Comaranil

Quick links to important sections

Comaranil

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Comaranil

What is Comaranil? Definition and Pharmacological Class

Property Description
Active ingredient Indapamide, Perindopril
Form Oral tablet
Pharmacological class Combined Antihypertensive Preparation
General use Management of high blood pressure (Essential Hypertension)
Origin Synthetic

Comaranil is defined as a synthetic, prescription-only medicine that is classified as a combined antihypertensive preparation, which is the therapeutic category for drugs used to manage high blood pressure, or essential hypertension. As a fixed-dose combination (FDC) product, delivered in a single oral dosage form, this formulation is clinically recognized for its superior efficacy in achieving and maintaining target blood pressure goals compared to single-agent therapies. This dual-component design serves as a foundational approach to long-term cardiovascular risk reduction.


Composition and Formulation: The Fixed-Dose Strategy

The formulation of Comaranil contains two principal active ingredients: Perindopril and Indapamide. Perindopril belongs to the Angiotensin-Converting Enzyme (ACE) Inhibitor class, acting as a prodrug that is metabolized into its active form. Indapamide is categorized as a unique thiazide-like diuretic, which helps prevent the body from absorbing excessive salt and water. The use of a single-pill combination (SPC) is the distinguishing feature of this product, and its format is often preferred for managing patients newly starting treatment or those needing to intensify their existing blood pressure control.


General Purpose and Synergistic Benefit

The general purpose of Comaranil is to achieve powerful antihypertensive efficacy by utilizing a dual mechanism of action against the factors that elevate blood pressure. The Perindopril component acts primarily to relax and widen the blood vessels (vasodilation), while the Indapamide component decreases the circulating fluid volume through increased excretion of salt and water (diuresis). This synergistic action ensures more comprehensive control over the circulatory system, delivering continuous support for managing elevated pressure. For an adult patient diagnosed with essential hypertension, this combination provides a comprehensive approach to lowering the force against the artery walls.

What side effects are possible with Comaranil?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Comaranil (Perindopril/Indapamide) as structured and classified by government regulatory authorities.


Adverse Reaction Classifications

The medicine's safety profile utilizes a standardized frequency classification to communicate the likelihood of documented adverse reactions. These effects are grouped into System-Organ-Classes (SOCs) based on the physiological systems they affect, such as Nervous system disorders (e.g., dizziness, headache) and Gastrointestinal disorders (e.g., nausea, abdominal pain). A dry cough is a common adverse reaction that is specifically documented in the regulatory profile.

Frequency Classification (Examples) Documented Adverse Reactions (Examples)
Common (1 to 10 out of 100 people) Dizziness, headache, cough, fatigue, nausea
Uncommon (1 to 10 out of 1,000 people) Mood alteration, dry mouth, skin rash, low blood pressure
Very Rare (Less than 1 out of 10,000 people) Pancreatitis, agranulocytosis, severe skin reactions

Serious Safety Considerations and Constraints

The regulatory profile identifies specific, clinically important safety concerns, including the risk of Angioedema (swelling of the face, tongue, or throat) and Acute renal failure. The medicine is subject to formal safety restrictions (contraindications) defining when it must not be used. These include a history of angioedema related to previous ACE inhibitor use, pre-existing severe renal impairment, severe hepatic impairment, and use during the second and third trimesters of pregnancy. Furthermore, regulatory notes indicate that hypotension (low blood pressure) is explicitly more likely at the initiation of treatment or during dose escalation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory description of Comaranil (Perindopril/Indapamide) overdose focuses on exaggerated pharmacological effects and resulting severe clinical outcomes. The primary documented manifestation is severe hypotension (excessively low blood pressure), which may be accompanied by signs of volume and electrolyte depletion, including confusion, dizziness, muscle cramps, and weakness.

Overdose can lead to life-threatening complications, most notably angioedema involving the larynx, which can cause acute airway obstruction, and, in rare instances associated with severe hypotension, acute renal failure. Population-specific notes indicate that the risk of acute renal failure is heightened in patients with pre-existing cardiac or ischemic disease, and the elderly may be more susceptible to severe hyponatremia.

Regulatory authorities mandate specific immediate actions. If serious symptoms occur, such as passing out or trouble breathing, seek immediate medical attention. Supportive management is required, and for severe hypotension, interventions like intravenous fluid replacement may be necessary. For angioedema of the airway, the immediate administration of subcutaneous epinephrine and measures to ensure a patent airway are described. The active component, Perindoprilat, is known to be dialyzable, and continuous monitoring of creatinine and potassium levels is required.

Therapeutic Uses of Comaranil

Comaranil is a medicine primarily used in the approach to high blood pressure, a condition also known as hypertension.

It is a combination product used to support blood pressure control in patients whose needs are not met by single-ingredient therapy. The medicine’s role is to contribute to managing blood pressure levels through its two components, perindopril and indapamide. The overall aim of this treatment is to help in the control of high blood pressure.

Comaranil is an antihypertensive used in the treatment of high blood pressure (hypertension). The primary therapeutic area is the long-term use in hypertension. This medication is considered beneficial in reducing the potential for cardiovascular events by assisting with blood pressure management.


Quick Fact: Used in the Management of Hypertension

Regulatory References

  1. Comaranil 4 mg/1,25 mg tabletten - Geneesmiddeleninformatiebank

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Comaranil

Comaranil (Perindopril/Indapamide) is indicated for use in adult patients with Essential Hypertension. Eligibility is governed by official regulatory documentation that establishes explicit contraindications and patient restrictions.

Category Official Regulatory Status
Absolute Contraindications History of angioedema related to any ACE inhibitor; severe hepatic impairment or hepatic encephalopathy; severe renal impairment (creatinine clearance < 30 mL/min); hypokalaemia; and hypersensitivity to perindopril, indapamide, or any sulphonamide derivative.
Pregnancy/Lactation Contraindicated in the second and third trimesters of pregnancy and during lactation (breastfeeding). Use in the first trimester is not recommended.
Dual Therapy Restriction Contraindicated with concomitant use of sacubitril/valsartan and with aliskiren in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m^2).
Age Restriction Not recommended for children and adolescents as safety and efficacy have not been established. Older adults may require treatment initiation at a lower dose based on renal function.

Eligibility is defined by regulatory bodies to exclude populations at high risk of complication, requiring strict adherence to these boundaries.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns for Comaranil, strictly based on regulatory labeling and government health authority information. The drug’s interaction profile is defined by restrictions on co-administration, pharmacodynamic reinforcement, and altered substance clearance.


Official Interaction Statements

  • Sacubitril/Valsartan is a contraindicated combination, requiring a 36-hour minimum separation window between doses to mitigate the risk of angioedema.
  • Aliskiren co-administration is strictly contraindicated in patients with Diabetes Mellitus or established Renal Impairment due to the associated risks of Dual RAAS Blockade.
  • The combination increases the serum concentration of Lithium due to reduced renal clearance of Lithium, leading to potential toxicity.
  • Co-administration with Potassium-sparing diuretics or Potassium supplements is not recommended due to the documented risk of hyperkalemia.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including high-dose aspirin, carry a risk of acute renal impairment and may officially attenuate the antihypertensive effect.
  • Alcohol (Ethanol) consumption may result in an additive hypotensive effect.

Interaction-Context Constraints

  • The drug is formally contraindicated in patients with Severe Renal Impairment (Creatinine Clearance < 30 mL/min), indicating heightened interaction risks in this population.
  • Severe Hepatic Impairment or Hepatic Encephalopathy also constitutes a formal contraindication.

Mechanism of Action

Comaranil functions as a direct antagonist of the P2Y12 receptor, a G protein-coupled receptor found on the surface of platelets. This mechanism is initiated by the selective binding of Comaranil to the receptor, thereby sterically preventing the binding of endogenous adenosine diphosphate ( ADP) to the platelet surface. Inhibition of the P2Y12 receptor modulates the intracellular signaling cascade, specifically preventing the subsequent activation of the GPIIb/IIIa receptor complex. Since the GPIIb/IIIa receptor complex mediates the cross-linking required for platelet-to-platelet adhesion, this action disrupts the final common pathway of aggregation. The net effect is a sustained modulation of platelet function, resulting in a systemic reduction in platelet aggregation potential without mentioning therapeutic outcomes.

Dosage and Administration Information

How to Use Comaranil

Comaranil is a fixed-dose combination product intended for long-term management and is administered exclusively via the oral route. The official instructions define a consistent, once-daily routine to be followed by adult patients. This regimen is based strictly on the dosages and instructions outlined in regulatory documentation.


Administration and Timing

Feature Official Guideline
Dosing Frequency Once daily.
Time of Day Should be taken preferably in the morning.
Food Relationship Must be taken before a meal.
Ingestion The tablet must be swallowed whole with water and should not be crushed or chewed.

Dosage and Adjustment Protocols

Comaranil is available in three fixed-dose strengths: 2 mg/0.625 mg, 4 mg/1.25 mg, and 8 mg/2.5 mg (Perindopril/Indapamide). The standard starting dose is typically one 2 mg/0.625 mg tablet daily. The dose may be adjusted to the next strength if blood pressure control is not achieved. The maximum daily dose is set at 8 mg/2.5 mg.


Procedural Conditions and Limitations

Official instructions provide specific limits for certain populations. For older adults, treatment should be initiated using the lowest available strength. For patients with moderate renal impairment (Creatinine Clearance between 30 and 60 mL/min), the maximum approved dose is limited to 2 mg/0.625 mg. The medicine is not recommended for use in children and adolescents. If a dose is missed, regulatory guidance is to take the next dose at the usual time and not to double the dose.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Comaranil


Evidence for Use in Essential Hypertension (High Blood Pressure)

Research regarding this combination (Perindopril/Indapamide) includes extensive Randomized Controlled Trials (RCTs) and observational studies focused on adults with Essential Hypertension. These studies have examined changes in office blood pressure and the rate at which participants achieved target blood pressure levels. Studies reported measurements of a reduction in blood pressure readings across diverse cohorts of hypertensive adults. Long-term trials have monitored major cardiovascular events and all-cause mortality, with research contributing to understanding how event rates evolved in the observed populations. Certain trials also explored outcomes linked to physiological strain or stress, such as shifts in specific biomarkers related to the heart and kidneys.


Research Focused on High Cardiovascular Risk

The evidence base includes large-scale Randomized Controlled Trials (RCTs) designed for secondary prevention in high-risk groups, such as those with established cerebrovascular disease (e.g., prior stroke) and Type 2 Diabetes Mellitus. Key study endpoints centered on the occurrence of fatal or non-fatal stroke, and the composite endpoint of Major Cardiovascular Events. Trials monitored the cumulative occurrence of events in these high-risk populations over defined time intervals. Documented outcomes in patients with Type 2 Diabetes Mellitus included measurements of renal biomarkers and observed patterns in mortality rates. The observed results for high-risk populations may not be directly translatable to all adults with hypertension without prior cardiovascular events.


What Is Still Uncertain About the Research Base

Research explored the very long-term outcomes and consistency of patterns beyond the five-year limit of most trials. Data for populations like children and adolescents are also insufficient. Furthermore, comparative evidence is lacking against every single alternative fixed-dose combination available, and certainty remains low for certain subgroups, as data are still emerging.

Key Studies & References

  1. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
  2. Public Assessment Report of the Medicines Evaluation Board in the Netherlands: Perindopril Tosilaat/Indapamide ratiopharm (Dual Combination Monograph)

Frequently Asked Questions (FAQ)

Common questions about Comaranil (FAQ)

Q: Can taking Comaranil affect the kidneys?

Regulatory information indicates that the ACE inhibitor component can affect kidney function. Acute renal failure or significant kidney damage is listed as a serious consideration. This risk is noted to be particularly relevant for patients with pre-existing kidney problems or when the drug is taken with certain other medicines.

Q: What are the general signs of low blood pressure that users report when taking Comaranil?

Official documents report that low blood pressure (hypotension) is a possible adverse event, particularly when starting treatment or following a dose increase. Symptoms reported that may be associated with hypotension include dizziness, headache, feeling faint, weakness, or lethargy.

Q: Are there any dietary restrictions, like avoiding potassium, while taking Comaranil?

Regulatory guidance advises avoiding the use of salt substitutes that contain potassium, as well as potassium supplements. This is due to the documented risk of developing hyperkalemia (high potassium levels in the blood) associated with its use.

Q: What should a patient generally expect if they feel dizzy or lightheaded after starting Comaranil?

Low blood pressure (hypotension) that can cause dizziness or light-headedness is reported to occur in the first few days after starting treatment or after a dose increase. Official patient materials describe resting or lying down as a measure that may be considered if this light-headedness occurs.

Q: Is there a risk of Comaranil causing a severe allergic reaction?

Severe allergic reactions, including swelling (angioedema), trouble breathing, rash, and fainting, are listed as serious safety concerns in official product information. The medication is formally contraindicated for use by patients who have a history of angioedema related to any previous ACE inhibitor use.

Q: Why does Comaranil treat both high blood pressure and certain heart failure conditions?

Comaranil is officially indicated for the management of essential hypertension (high blood pressure). However, the ACE inhibitor component (Perindopril) is commonly utilized in other contexts, including in the management of certain heart failure conditions. This common usage pattern reflects the general therapeutic scope of this component.

Q: Is it generally possible to stop taking Comaranil once blood pressure is consistently controlled?

Regulatory guidance states that high blood pressure is not cured by this medicine and that continuous, regular intake is important even if symptoms improve. Official warnings emphasize that discontinuation is defined in the regulatory documentation as a process that requires the input of a healthcare professional.

Q: What is the meaning of the official warning about Comaranil being a 'prodrug'?

Official regulatory descriptions define the Perindopril component as a 'prodrug.' This term means it is an inactive substance when taken, and the body converts it (metabolizes it) in the liver into its active form before it can start working.

Q: What is the official classification of Comaranil (e.g., is it a generic or brand name)?

The product is officially categorized as a 'Combined Antihypertensive Preparation.' While the specific ingredients (perindopril and indapamide) are available as generics, the single-pill combination format is marketed globally under various brand names.

Q: How long does it usually take for Comaranil to start working to lower blood pressure?

Regulatory guidance indicates that a patient may need to take the medicine for several weeks before the full blood pressure-lowering benefit is achieved. Consistent daily use is described in official documentation as required to reach and maintain the maximum benefit.

Q: Does Comaranil cause sexual side effects, such as reduced libido or performance issues?

According to official adverse event data, male sexual dysfunction has been reported in clinical trials involving the perindopril component. However, the reported frequency of this adverse event is generally low, similar to that seen in groups taking an inactive substance (placebo).

Q: Does Comaranil interact with common heart medicines like beta-blockers?

Regulatory documents note that this combination has known interactions with other high blood pressure treatments, including beta-blockers. Official information states that when these medicines are taken together, close monitoring and caution are typically required based on the regulatory profile.

Q: Are there any reported interactions between Comaranil and herbal supplements?

Official patient information emphasizes the importance of informing the prescribing doctor about all other medicines and products being taken, which includes herbal products and supplements. This is recommended because limited specific interaction information may be available for these combinations.

Q: How long does the blood pressure-lowering effect of Comaranil typically last?

Official pharmacokinetics data for the active component support a long half-life. This characteristic is described as supporting a sustained blood pressure-lowering effect that lasts over a 24-hour period, which aligns with the recommended once-daily dosing frequency.

Q: Are there any specific medical monitoring tests, like blood tests, required while taking Comaranil?

Regulatory documents describe the need for regular medical monitoring for patients using Comaranil. This typically includes blood tests to check plasma electrolytes, such as potassium and sodium, as well as monitoring of kidney function.

Q: What are the warnings about using Comaranil if a patient is dehydrated from sickness or exercise?

Official documents caution that the risk of excessive low blood pressure (hypotension) is higher in patients who are volume-depleted or dehydrated. This state can be caused by conditions such as recent vomiting, diarrhea, or excessive sweating.

Q: Does Comaranil affect blood sugar levels, especially for people with diabetes?

Official product information notes that careful monitoring is required for patients diagnosed with diabetes mellitus. This is because certain drug interactions and the diuretic component (Indapamide) may potentially affect the body's blood sugar balance.

Q: Can I exercise or be in hot weather while taking Comaranil?

Official patient information states that engaging in physical exercise or being in hot weather may increase the likelihood of experiencing low blood pressure (hypotension). This may lead to sensations of dizziness or light-headedness.

Q: Does Comaranil interact with lithium or gold preparations?

Regulatory documents indicate that the product is known to increase the serum concentration of Lithium, which carries a risk of toxicity. Official interaction information also includes reports of adverse events with certain gold preparations, especially when given intravenously.

Q: How is Comaranil elimination or cleared from the body?

According to official pharmacokinetic information, the Perindopril component is primarily eliminated by the kidneys. The Indapamide component is largely metabolized in the liver, with the resulting inactive metabolites being cleared from the body primarily through urine and also through feces.

How should Comaranil be stored and disposed of?

The storage and disposal of Comaranil must adhere strictly to the conditions specified in the official regulatory labeling.

Official Storage and Handling

Comaranil tablets must be stored in the original packaging to ensure protection from moisture and should be kept at a temperature that remains below 30 C. To prevent harm, it is an explicit requirement to keep this medicine out of the sight and reach of children at all times. The product must not be used after the expiration date printed on the container.

Disposal Requirements

To protect the environment, unused or expired Comaranil must not be thrown away via wastewater or general household waste. The official procedure requires consulting a pharmacist for instructions on how to properly discard any remaining or unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Comaranil found in:

A-Z Index: